Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 2017

Sort by

Sort Order Select

Journal Articles

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment

Austin G. Kulasekararaj, Jong Wook Lee, Christopher J. Patriquin, Caroline I. Piatek, Alexander Röth, Wilma Barcellini, Robert A. Brodsky, Jun-ichi Nishimura, Ji Yu, Mohammed Mahdi, Régis Peffault de Latour

Blood Adv (2025) 9 (19): 4936–4945.

https://doi.org/10.1182/bloodadvances.2024015490

Published: 2025

Includes: Supplemental data

Journal Articles

Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease

Husham Sharifi, Carson Tyler Moss, Zayan Musa, Alexander Bell, Christian O’Donnell, Carlos Hernandez Borges, Efthymia Iliana Matthaiou, Laura Johnston, Craig J. Galban, Ajay Sheshadri, Gregory Yanik, Guang-Shing Cheng, Joe L. Hsu

Blood Adv (2025) 9 (19): 5024–5037.

https://doi.org/10.1182/bloodadvances.2025016122

Published: 2025

Includes: Supplemental data

Journal Articles

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Andrew Kowalski, Jill Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James Hoffman, Abhishek Pandey, Dickran Kazandjian, Ola Landgren

Blood Adv (2025) 9 (19): 4979–4986.

https://doi.org/10.1182/bloodadvances.2025016911

Published: 2025

Journal Articles

Dose-reduced apixaban for secondary prophylaxis in patients with severe obesity: a single center analysis

Eliot A. Rapoport, Noelle W. Townsend, Nadine Farhat, Parth Patel, Henny H. Billett

Blood Adv (2025) 9 (19): 4776–4779.

https://doi.org/10.1182/bloodadvances.2025016037

Published: 2025

Journal Articles

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani, John Timmerman, Nathalie A. Johnson, David Lavie, Kannan Thiagarajan, Brian G. Topp, Pallavi Pillai, Alex F. Herrera

Blood Adv (2025) 9 (19): 4987–4995.

https://doi.org/10.1182/bloodadvances.2024014654

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

Michael Sang Hughes, Samuel Pan, Rajshekhar Chakraborty, Jayant Raikhelkar, Mathew S. Maurer, Markus Y. Mapara, Andrew Eisenberger, Suzanne Lentzsch, Divaya Bhutani

Blood Adv (2025) 9 (19): 4946–4950.

https://doi.org/10.1182/bloodadvances.2025016731

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia

Jorge J. Castillo, Alberto Guijosa, John N. Allan, Tanya Siddiqi, Ranjana H. Advani, Catherine A. Flynn, Kirsten Meid, Nina Budano, Julia Nguyen, Andres Ramirez-Gamero, Nicholas Tsakmaklis, Zachary R. Hunter, Christopher J. Patterson, Steven P. Treon, Shayna Sarosiek

Blood Adv (2025) 9 (19): 4842–4847.

https://doi.org/10.1182/bloodadvances.2025016890

Published: 2025

Journal Articles

Extravascular hemolysis in PNH

Jeff Szer

Blood Adv (2025) 9 (19): 4977–4978.

https://doi.org/10.1182/bloodadvances.2025016873

Published: 2025

Journal Articles

Moving the needle on chronic GVHD of the lung

Julie R. Boiko, Kenneth R. Cooke

Blood Adv (2025) 9 (19): 5038–5039.

https://doi.org/10.1182/bloodadvances.2025017297

Published: 2025

Journal Articles

Primary and Secondary Stroke Prophylaxis in Children with Sickle Cell Anemia: A Meta-Analysis

Hemalatha G. Rangarajan, Jose A. Mejias, Alison Paige Gehred, Mark J. Rodeghier, Michael R DeBaun

Blood Adv bloodadvances.2023012544.

https://doi.org/10.1182/bloodadvances.2023012544

Published: 2025

Includes: Supplemental data

Journal Articles

Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology

Waleed Alduaij, Laurie H. Sehn, Jean-Nicolas Champagne, Brett Collinge, Susana Ben-Neriah, Aixiang Jiang, Laura K Hilton, Merrill Boyle, Barbara Meissner, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Kerry J. Savage, Diego Villa, Alina S. Gerrie, Ciara L Freeman, Andrew J Mungall, Christian Steidl, David W. Scott

Blood Adv bloodadvances.2025017282.

https://doi.org/10.1182/bloodadvances.2025017282

Published: 2025

Includes: Supplemental data

Journal Articles

Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability

Blood Adv bloodadvances.2025017035.

https://doi.org/10.1182/bloodadvances.2025017035

Published: 2025

Includes: Supplemental data

Journal Articles

Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies

Hisayuki Yokoyama, Noriko Fukuhara, Koji Ando, Hiroatsu Iida, Takahiro Yamauchi, Suguru Fukuhara, Koji Izutsu, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Eiji Takahara, Shingo Shoji, Akio Mizutani, Daisuke Morishita, Robert Westley Oda, Hiroshi Miyake, Noboru Yamamoto

Blood Adv bloodadvances.2025017601.

https://doi.org/10.1182/bloodadvances.2025017601

Published: 2025

Includes: Supplemental data

Journal Articles

FLT3-ITD measurable residual disease from the QuANTUM-First trial

Blood Adv bloodadvances.2025016444.

https://doi.org/10.1182/bloodadvances.2025016444

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Combining Midostaurin and Gemtuzumab Ozogamicin with Induction Chemotherapy in FLT3 mutated AML

Blood Adv bloodadvances.2025017244.

https://doi.org/10.1182/bloodadvances.2025017244

Published: 2025

Includes: Supplemental data

Journal Articles

Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations

Alexandra Power-Hays, Kathryn E. McElhinney, Thomas N Williams, George Mochamah, Peter Olupot-Olupot, George Paasi, Marvin E. Reid, Angela E Rankine-Mullings, Robert O Opoka, Chandy C. John, Patrick T. McGann, Charles T. Quinn, Nieko C Punt, Luke R. Smart, Susan E. Stuber, Teresa S. Latham, Alexander A. Vinks, Russell E. Ware

Blood Adv bloodadvances.2025017254.

https://doi.org/10.1182/bloodadvances.2025017254

Published: 2025

Journal Articles

Long-term outcomes of genome-edited “universal” CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center

Daniela Guardo, Avijeet Kumar Mishra, Hebatalla Rashed, Kimberly Gilmour, Stuart Adams, Danielle Pinner, Martin Sauer, Ajay Vora, Paul Veys, Vesna Pavasovic, Kanchan Rao, Waseem Qasim

Blood Adv (2025) 9 (18): 4750–4754.

https://doi.org/10.1182/bloodadvances.2025016366

Published: 2025

Includes: Supplemental data

Journal Articles

Gene-edited CAR T cells: going the distance in B-ALL

John A. Ligon, Nirali N. Shah

Blood Adv (2025) 9 (18): 4755–4756.

https://doi.org/10.1182/bloodadvances.2025017508

Published: 2025

Journal Articles

Risk Biomarkers of Chronic Graft-versus-host disease in Children aged 10 years or younger and Children/adults Older than 10 years

Anna Crawford Ferreira, Debjani Dutta, Courtney M Rowan, Jamie Renbarger, Kenneth R Cooke, Paul A. Carpenter, Robert A Krance, Christine N Duncan, Conrad Russell Y. Cruz, David A Jacobsohn, Catherine M. Bollard, Elizabeth Hill, Sophie Paczesny

Blood Adv bloodadvances.2025016624.

https://doi.org/10.1182/bloodadvances.2025016624

Published: 2025

Includes: Supplemental data

Journal Articles

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Pierre Stephan, Roberta Di Blasi, Louise Roulin, Jean Galtier, Julien Calvani, Véronique Meignin, Marie Donzel, Alexandra Traverse-Glehen, Elsa Poullot, Marie Parrens, Vivien Dupont, Alexandra Marquet, Steven Le Gouill, Roch Houot, Francois-Xavier Gros, François Lemonnier, Emmanuel Bachy, Catherine Thieblemont, Pierre Sesques

Blood Adv (2025) 9 (18): 4693–4704.

https://doi.org/10.1182/bloodadvances.2025015834

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment

Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Dose-reduced apixaban for secondary prophylaxis in patients with severe obesity: a single center analysis

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia

Extravascular hemolysis in PNH

Moving the needle on chronic GVHD of the lung

Primary and Secondary Stroke Prophylaxis in Children with Sickle Cell Anemia: A Meta-Analysis

Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology

Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability

Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies

FLT3-ITD measurable residual disease from the QuANTUM-First trial

Safety and Efficacy of Combining Midostaurin and Gemtuzumab Ozogamicin with Induction Chemotherapy in FLT3 mutated AML

Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations

Long-term outcomes of genome-edited “universal” CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center

Gene-edited CAR T cells: going the distance in B-ALL

Risk Biomarkers of Chronic Graft-versus-host disease in Children aged 10 years or younger and Children/adults Older than 10 years

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only